Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

THE TRADES Stitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1

	0	inpiete ii Kriowii			
	Application Number 10/533,025				
	Filing Date	November 20, 2006 Stephen Behr, et al.			
	First Named Inventor				
	Art Unit	1655			
	Examiner Name	Qiuwen Mi			
	Attorney Docket Number	20CF-144430			

Complete if Vacuus

U. S. PATENT DOCUMENTS						
Examiner	Cite No.1	ite Document Number	Publication Date	Name of Patentee or .	Pages, Columns, Lines, Where	
Initials*	NO.	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			•			
					1	
	1	· .			•	
	$\downarrow \qquad \downarrow$					
	1				· 	

3

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.¹	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ [¢]	
-		CA 406,408	07-28-1942	Tannin Corp./Shelton			
		EP 0 870 507 A1	10-14-1998	Farmo-Nat Ltd./Levin			
		GB 544,615	04-21-1942	Tannin Corp./Shelton			
		JP 03287532 (abstract)	12-18-1991	Daicel Chemical Ind.			
		JP 2002-087973 (abstract and copy)	03-27-2002	Kao Corp./Oji Paper			
		WO 2004/019961 A1	03-11-2004	Bio-Pharmacopae Design Int'l. Inc./Cyr			

Examiner Signature	Date Considered	
C.g.,	 	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10533025 - GAU: 1655 PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

20CF-144430

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/533,025 INFORMATION DISCLOSURE **Filing Date** November 20, 2006 STATEMENT BY APPLICANT First Named Inventor Stephen Behr, et al. Art Unit 1655 (Use as many sheets as necessary) **Examiner Name** Qiuwen Mi

Attorney Docket Number

3

Sheet

2

٠	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	-	ARAKAWA, Kazuhito, et al. "Multifunctional Anti-Angiogenic Activity of the Cyclic Peroxide Ano-2 with Antitumor Activity," <i>Int. J. Cancer</i> , 2002, pp. 220-227, Vol. 100, Wiley-Liss, Inc., UICC.				
		BERGERS, Gabriele, et al. "Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis," <i>Nature Cell Biology</i> , October 2000, pp. 737-744, Vol. 2, Macmillan Magazines Ltd., http://cellbio.nature.com.				
·		BOEHM, Marcus F., et al. "Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis – Retinoids: biological function and use in the treatment of dermatological diseases," <i>Exp. Opin. Invest. Drugs</i> , 1995, pp. 593-612, Vol. 4 (7), Ashley Publications Ltd., ISSN 1354-3784.				
	·	GROSS, Stephen C., et al. "Antineoplastic Activity of Solidago virgaurea on Prostatic Tumor Cells in an SCID Mouse Model," <i>Nutrition and Cancer</i> , 2002, pp. 76-81, Vol. 43, No. 1, Lawrence Erlbaum Associates, Inc.				
		KIM, Bae-Hwan, et al. "The mechanism of retinol-induced irritation and its application to anti-irritant development," <i>Toxicology Letters</i> , 9/1/2003, pp. 65-73, Vol. 146, Elsevier Ireland Ltd.				
		KLIGMAN, A.M., et al. "Topical retinol improves cellulite," <i>Journal of Dermatological Treatment</i> , 1999, pp. 119-125, Vol. 10, JDT, ISSN 0954-6634.				
		KRAUS, Josef, et al. (abstract). "Antitumor polysaccharides from <i>Solidago</i> species," <i>Deutsche Apotheker Zeitung</i> , 12/26/1986, pp. 2045-9, Vol. 126 (38), Pharm. Biol., Univ. Regensburg, Regensburg, Germany, ISSN: 0011-9857.				
,		LIOTTA, L.A., et al. "Metastatic potential correlates with enzymatic degradation of basement membrane collagen," <i>Nature</i> , 3/6/1980, pp. 67-68, Vol. 284, Macmillan Journals Ltd., Nature Publishing Group.				
		NAKAHARA, Hirokazu, et al. "Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion," <i>Proc. Natl. Acad. Sci. USA</i> , July 1997, pp. 7959-7964, Vol. 94, The National Academy of Sciences.				
		PARK, Moon-Taek, et al. "Glucocorticoid Receptor-induced Down-regulation of MMP-9 by Ginseng Components, PD and PT Contributes to Inhibition of the Invasive Capacity of HT1080 Human Fibrosarcoma Cells," <i>Molecules and Cells,</i> 1999, pp. 476-483, Vol. 9, No. 5, Springer-Verlag.				

Examiner	Date ·	
Signoturo		
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10533025 - GAU: 1655

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

	Substitute for form 1449B/PTO				Complete if Known			
					Application Number	10/533,025		
	INFO	DRMATION DIS	CLOS	URE	Filing Date	November 20, 2006		
	STA	TEMENT BY AF	PPLIC	ANT	First Named Inventor	Stephen Behr, et al.		
					Art Unit	1655		
		(Use as many sheets as nec	essary)		Examiner Name	Qiuwen Mi		
S	heet	3	of	3	Attorney Docket Number	20CF-144430		

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		SUTHAR, A.C., et al. "A review on ginger (Zinger officinale): Pre-clinical and clinical trials," Indian Journal of Traditional Knowledge, January 2002, pp. 51-61, Vol. 2 (1).	
		VARANI, James, et al. "Molecular Mechanisms of Intrinsic Skin Aging and Retinoid-Induced Repair and Reversal," <i>JID Symposium Proceedings</i> , 1998, pp. 57-60, Vol. 98, The Society for Investigative Dermatology, Inc.	
		International Search Report for International Application No. PCT/CA2002/00285 dated July 23, 2002, European Patent Office.	
		Office Action for US Patent Application No. 10/091,331 dated October 10, 2002.	
	ļ	Office Action for US Patent Application No. 10/091,331 dated March 21, 2003.	
		Office Action for US Patent Application No. 10/091,331 dated November 14, 2003.	
		Office Action for US Patent Application No. 10/091,331 dated July 27, 2004.	
		Office Action for US Patent Application No. 10/526,387 dated May 2, 2008.	
	ļ	Office Action for US Patent Application No. 11/577,292 dated October 19, 2009.	
		Office Action for US Patent Application No. 12/263,114 dated September 23, 2009.	
-			

Examiner	Oilesson Mil	Date	05/24/2010
Signature	/Qiuwen Mi/	Considered	03/24/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.